News

LeMaitre (NASDAQ:LMAT) Misses Q4 Sales Targets, Stock Drops 11%

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 14% year on year to $55.72 million. Next quarter’s revenue guidance of $57.7 million underwhelmed, coming in 1.6% below analysts’ estimates. Its GAAP profit of $0.49 per share was in line with analysts’ consensus estimates.

Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.77 per share was 15.1% above analysts’ consensus estimates.

The Pennant Group’s (NASDAQ:PNTG) Q4 Sales Top Estimates, Full-Year Sales Guidance is Optimistic

Senior living provider The Pennant Group (NASDAQ:PNTG) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 29.4% year on year to $188.9 million. The company’s full-year revenue guidance of $832.5 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP profit of $0.24 per share was in line with analysts’ consensus estimates.